← All organizations
Highest phase reached
Phase 3
First clinical trial
Apr 1, 2015Last known activity
May 6, 2025
Timeline
2010s
- Apr 1, 2015
Japan Agency for Medical Research and Development— Founded
Drugs by trial phase (25 distinct, 24 trials)
Phase 3 (10 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Indications
Studied for
- Autism Spectrum Disorder
- Autistic Disorder
- Autoimmune Diseases
- Carcinoma, Non-Small-Cell Lung
- Child Development Disorders, Pervasive
- Cholangitis
- Collagen Diseases
- Fibrosis
- Hemophilia A
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Liver Cirrhosis
- Liver Cirrhosis, Biliary
- Lung Neoplasms
- Pancreatic Neoplasms
- Polyradiculoneuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
- Stroke
- Syndrome
Recent trials (24)
- NCT07227246CollaboratorPhase 3May 6, 2025
- NCT06983210CollaboratorPhase 2May 1, 2025
- NCT06853496CollaboratorPhase 1Mar 13, 2025
- NCT06441994CollaboratorPhase 1May 24, 2024
- NCT06223919CollaboratorPhase 3Dec 16, 2023
- NCT06144086CollaboratorPhase 2Dec 5, 2023
- NCT06361433CollaboratorPhase 1/Phase 2Dec 1, 2023
- NCT05646511CollaboratorPhase 3Nov 21, 2022
- NCT05679570CollaboratorPhase 2Jul 12, 2022
- NCT05064618CollaboratorPhase 1/Phase 2Aug 23, 2021
- NCT04993586CollaboratorPhase 1/Phase 2Jul 29, 2021
- NCT04688034CollaboratorPhase 1Jan 15, 2021
- NCT04655625CollaboratorPhase 2/Phase 3Nov 23, 2020
- NCT04465968CollaboratorPhase 3Sep 1, 2020
- NCT04463472CollaboratorPhase 1/Phase 2Jun 29, 2020
Details
- Founded
- Tokyo, JP Apr 1, 2015
- Last known activity
- May 6, 2025